Background Paper 6.21
Hearing Loss

By Béatrice Duthey, Ph.D
20 February 2013
Table of Contents

Executive Summary .......................................................................................................................... 4

1. Introduction ................................................................................................................................. 5
   1.1 Hearing Loss definitions ............................................................................................................ 5
   1.2 Possible Causes of hearing loss ............................................................................................... 7
       1.2.1 Ear infections .................................................................................................................. 7
       1.2.2 Untreated infections during childhood ........................................................................... 8
       1.2.3 Congenital hearing loss ................................................................................................... 8
       1.2.4 Injury/trauma .................................................................................................................. 9
       1.2.5 Aging .............................................................................................................................. 9
       1.2.6 Exposure to prolonged or excessive noise ....................................................................... 9
       1.2.7 Medications and other chemicals that are toxic to the ear .............................................. 9
       1.2.8 Nutritional Deficiency Causes ....................................................................................... 10
   1.3 Diagnosis ............................................................................................................................... 11
       1.3.1 New borns and Infants Diagnosis ................................................................................. 11
       1.3.2 Children and Adult Diagnosis ....................................................................................... 11

2. What are the Epidemiological Trends for Europe and the World? ........................................... 11
   2.1 General .................................................................................................................................. 11
   2.2 Prevalence ............................................................................................................................ 12
       2.2.1 Prevalence in the world ................................................................................................. 12
       2.2.2 Prevalence in Europe ..................................................................................................... 15

3. What is the control Strategy? ..................................................................................................... 17
   3.1 Prevention Measures .............................................................................................................. 17
       3.1.1 Primordial Prevention .................................................................................................. 17
       3.1.2 Secondary Prevention ................................................................................................. 18
       3.1.3 Tertiary prevention ...................................................................................................... 18
   3.2 Therapies ............................................................................................................................... 19

4. What is known of the Availability, Feasibility and Sustainability of the Control Strategy? .... 20
   4.1 The European Burden of Hearing Loss and cost .................................................................. 20
   4.2 Feasibility and Control Strategy .......................................................................................... 21

5. Why does the Disease Burden Persist? ..................................................................................... 22
   5.1 Lack of awareness of the problem ......................................................................................... 22
   5.2 Poor Diagnosis ..................................................................................................................... 23
   5.3 A lack of epidemiological data .............................................................................................. 23
   5.4 Poor living conditions and lack of vaccination coverage ..................................................... 23
   5.5 Underuse of hearing devices ................................................................................................. 23
   5.6 Exposure to noise .................................................................................................................. 24
   5.7 Aging of the population ........................................................................................................ 24
6. Past/Current Research into Pharmaceutical Interventions for this Condition

6.1 Antioxidants and ROS scavengers
6.1.1 Sodium thiosulfate (STS)
6.1.2 Alpha Lipoic Acid
6.1.3 N-acetylcysteine
6.1.4 Ginkgo Biloba
6.1.5 Dietary supplements: Vitamins and minerals

6.2 Anti-inflammatory agents
6.2.1 Salicylate/Aspirin
6.2.2 Steroids
6.2.3 TNF-α inhibitors

6.3 Anti-apoptotic agents

6.4 New Promising drug candidates from animal studies
6.4.1 RNA interference
6.4.2 Nanotechnology for drug administration to the cochlea
6.4.3 D-methionine
6.4.4 Resveratrol
6.4.5 Neurotrophic factors
6.4.6 Caspase Inhibitors
6.4.7 Stem cell transplantation
6.4.8 Targeted Neural Stimulation

7. What is the Current “Pipeline” of Products that Are to Be Used for this Particular Condition?

7.1 Extended Wear Hearing Aids
7.2 Cochlear Implants
7.3 Middle Ear Implants
7.4 Sign Language

8. What is the Current Status of Institutions and Human Resources Available to Address the ear disease and hearing impairment and disability?

8.1 Public Fundings
8.1.1 European Sources of Funding
8.1.2 Initiatives from the World Health Organization (WHO)
8.2 Private Fundings

9. Gaps between current research and potential research issues which could make a difference

10. Conclusion

References

Annexes

Annex 6.21.1: Countries and territories in analysis regions
Annex 6.21.2: DALYs caused by hearing loss, by age group, regions and sex
Annex 6.21.3: Cochrane study summary on medical interventions
Executive Summary

The World Health Organization (WHO) estimated in 2008 that over 360 million persons have disabling hearing loss which represents 5.3% of the world population. Eighty per cent of these people reside in low- or middle-income countries (LMIC). In Europe, about 52 million people are affected and more than 50% of European adults beyond 65 years old present slight to severe hearing loss according 2010 estimates. Epidemiological surveys are scarce and particularly in low-income countries as a result of difficulty field testing of hearing levels, poor diagnosis and reporting as well as lack of awareness of the problem leading to shortage of funding to conduct surveys. With the aging of the world population these numbers are expected to rise substantially.

Hearing loss is an important public health concern with substantial economic and societal costs. In infants and children hearing impairment retards developmental language and educational progress. In adults, it causes difficulties in both professional and social life as well as stigmatization. Apart from consequences to the individual person, hearing loss also leads to high costs to society.

Hearing impairment can be caused by a number of factors including infections during childhood such as measles, mumps and meningitis, chronic otitis media, exposure to excessive or prolonged noise, head/neck injuries, use of ototoxic medications such as certain types of chemotherapies and antibiotics, industrial solvents, congenital abnormalities and infections and perinatal problems, certain nutritional deficiencies, genetic disorders and aging.

Use of hearing devices such as aids and cochlear implants as well as sign language, lip reading and special amplification systems in schools are strategies to help affected people manage their communication. Although the prevalence of hearing impairment is high, very little research towards pharmaceutical treatment has been made in the previous decades.

Within the past few years, exciting research on genetic manipulation, gene therapy, and stem cell transplantation as well pharmaceutical agents, suggest that a therapeutic treatment for hearing loss may eventually be possible in the future.
1. Introduction

In 2004, Warren Kaplan and Richard Laing wrote the Priority Medicines for Europe and the World Report. This report did not address hearing loss, but by 2012 the burden of disease caused by hearing loss justified an in-depth study.

The ability to hear is critical to understanding the world around us as well as interacting with each other. Hearing impairment is the most frequent sensory deficit in human populations and affects newborns, children, adults and elderly.\(^1\)

In children, hearing loss can be inherited, or acquired as sequelae of viral or bacterial infections during pregnancy, childhood or complications during birth, also due to ototoxic drugs, excessive noise and specific nutritional deficiencies. In adults, the major causes of hearing loss are presbycusis which is related to ageing, excessive and prolonged exposure to noise, acoustic and physical trauma, and use of ototoxic drugs such as certain types of chemotherapies, antibiotics, and industrial chemicals.

This background report reviews global data on hearing loss among children and adults in Europe and the world and provides estimates on disability prevalence and costs of management. In addition this report reviews scientific progress and identifies gaps and opportunities for research interventions towards prevention or cure.

There has been exciting research performed recently on a possible preventive treatment of hearing loss caused by ototoxic medications or high level of noise. Following the success of research from animal experiments, several promising clinical trials have been launched. These trials offer exciting possibilities not only for prevention of hearing loss but also for a possible treatment to restore auditory functions.

1.1 Hearing Loss definitions

Hearing is the ability to perceive sounds. Sound occurs over a wide spectrum of frequencies. The human ear is sensitive to a frequency band within that spectrum expressed in decibels (dB). Frequencies capable of being heard by humans are called audio or sonic. The range is typically considered to be between 20 Hz and 20,000 Hz (Hertz). Frequencies higher than audio are referred to as ultrasonic, while frequencies below audio are referred to as infrasonic.\(^1\) Loss of the ability to hear sound frequencies in the normal range of hearing is called hearing impairment.

There is a diversity of definitions of hearing impairment, thus, comparison among studies is difficult and may be invalid. The definition used by any study should always be checked before attempting to make such comparisons. The World Health Organization (WHO) defines disabling hearing impairment in adults as a permanent unaided hearing threshold level (average for frequencies 0.5, 1, 2, 4 kHz (kiloHertz)) for the better ear of 41 dB or greater (WHO, 2001).\(^2\) In children under 15 years of age, disabling hearing impairment is defined as permanent unaided hearing threshold level (average for frequencies 0.5, 1, 2, 4 kHz) for the better ear of 31 dB or greater. The WHO classifies hearing impairment into five grades, as shown in Table 6.21.1. Categories of hearing impairment range from “no impairment” to
“profound impairment” according to the threshold. Thus, for both adults and children “disabling hearing impairment” means the same as moderate or worse hearing impairment.

Table 6.21.1. WHO grades of hearing impairment

<table>
<thead>
<tr>
<th>Grade of Impairment</th>
<th>Audiometric ISO value (average of 500, 1000, 2000, 4000 Hz)</th>
<th>Impairment description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (no impairment)</td>
<td>25 dBHl or less (better ear)</td>
<td>No or very slight hearing problems. Able to hear whispers</td>
</tr>
<tr>
<td>1 (Slight impairment)</td>
<td>26-40 dBHl (better ear)</td>
<td>Able to hear and repeat words spoken in normal voice at 1 metre</td>
</tr>
<tr>
<td>2 (Moderate impairment)</td>
<td>41-50 dBHl (better ear)</td>
<td>Able to hear and repeat words using raised voice at 1 metre</td>
</tr>
<tr>
<td>3 (Severe impairment)</td>
<td>61-80 dBHl (better ear)</td>
<td>Able to hear some words when shouted into better ear</td>
</tr>
<tr>
<td>4 (Profound impairment including deafness)</td>
<td>81 dBHl or greater (better ear)</td>
<td>Unable to hear and understand even a shouted voice</td>
</tr>
</tbody>
</table>


The auditory pathway comprises the external ear, the middle ear and the inner ear, followed by the auditory nerve ending up in the auditory centres in the auditory cortex.³

- The external ear consists of the pinna, ear canal and eardrum. Sound travels down the ear canal, striking the eardrum and causing it to move or vibrate.
- The middle ear is a space behind the eardrum that contains three small bones called ossicles. This chain of tiny bones is connected to the eardrum at one end and to the oval window at the other end which connects to the inner ear. Vibrations from the eardrum cause the ossicles to vibrate which, in turn, creates movement of the fluid in the inner ear.
- Movement of the fluid in the inner ear, or cochlea, causes changes in tiny structures called hair cells. This movement of the hair cells sends electric signals from the inner ear up the auditory nerve (also known as the hearing nerve) to the brain.

The brain then interprets these electrical signals as sound. Figure 6.21.1 shows the different compartment of the ear described above.
There are three basic types of hearing loss: conductive hearing loss, sensorineural hearing loss and mixed hearing loss based on which part of the auditory system is damaged.

- **Conductive hearing loss** occurs when sound is not conducted efficiently through the external ear canal to the eardrum and the ossicles of the middle ear. This type of hearing loss usually involves a reduction in sound level or the ability to hear faint sounds and can be corrected medically or surgically.

- **Sensorineural hearing loss** (SNHL) occurs when there is damage to the inner ear (cochlea), or to the nerve pathways from the inner ear to the brain. Sensorineural hearing loss is the most common type of hearing loss and cannot be medically treated so far. Persons affected have difficulties in hearing faint sounds even when the speech is loud enough.

### 1.2 Possible Causes of hearing loss

#### 1.2.1 Ear infections

Hearing loss can be caused by viral, bacterial or parasitic infections. Middle ear infections are important causes of hearing impairment for many children in the world. For example, chronic suppurative otitis media is the commonest cause of hearing loss in children in developing countries. Children are more prone to ear infections than adults as the Eustachian tube, the passage between the middle ear and the back of the throat is smaller and more horizontal than in adults. This allows it to be more easily blocked by inflammation from infections in the ear or adenoid and tonsillar enlargement which blocks the Eustachian tube and impairs the ventilation and drainage of the middle ear, thus preventing drainage of purulent fluids.
Chronic suppurative otitis media (CSOM), caused by chronic bacterial infections in the middle ear, is an important cause of hearing loss in low- and middle-income countries. Chronic otitis media is associated with perforation of the tympanic membrane and can lead to death from complications such as meningitis or brain abscess. According to the WHO “High rates of chronic otitis media have been attributed to overcrowding, inadequate housing, poor hygiene (through transmission of the pathogens by physical contact with a contaminated individual, inhalation of infected droplets, or contact with an infected surface), lack of breastfeeding, poor nutrition, passive smoking, anecdotally to wood-burning smoke, high rates of nasopharyngeal colonization with potentially pathogenic bacteria, and inadequate or unavailable health care. Poverty is a major risk factor in developing countries and certain neglected populations.”

Because of availability of ear care facilities with appropriately trained staff together with topical and systemic antibiotic therapies, chronic otitis media has markedly decreased in high income countries. However, it is still a serious public health concern in many low- and middle-income countries.

1.2.2 Untreated infections during childhood

The difficulty of access to health care facilities and other factors such as poor personal hygiene and overcrowding cause many children in low- and middle-income countries to become deaf or hard of hearing following infections such as meningitis, measles, viral encephalitis, chicken pox, influenza, mumps or other viral infections. In the so-called “meningitis belt” in the sub-Saharan Sahelian region of Africa, epidemics of meningococcal meningitis happen regularly, and many survivors are left with sensori-neural hearing loss and other neurological sequelae.

1.2.3 Congenital hearing loss

The term congenital hearing loss means that hearing loss is present at birth. Congenital hearing loss can be caused by genetic or non-genetic (acquired) factors. Non-genetic factors that are known to cause congenital hearing loss are linked to pregnancy and birth delivery and include:

- Maternal infections during pregnancy, such as rubella (German measles), Cytomegalovirus, or herpes simplex virus
- Prematurity
- Low birth weight
- Cranio-facial abnormalities
- Birth injuries
- Toxins including certain drugs and alcohol consumed by the mother during pregnancy
- Complications associated with severe jaundice in the newborn baby often due to maternal-fetal blood type incompatibility
- Maternal diabetes
- Lack of oxygen (anoxia)

Hearing loss from genetic defects can be present at birth or develop later on in life. Most genetic hearing loss can be described as autosomal recessive or autosomal dominant, linked to X-chromosome or to mitochondrial inheritance patterns. In autosomal recessive hearing loss, both parents carry the recessive gene and pass it along to the child. Marriages between
cousins, especially first cousins, which occur in certain communities, favour this type of genetically inherited disorders.\textsuperscript{9}

Autosomal dominant hearing loss occurs when an abnormal gene from one parent is able to cause hearing loss even though the matching gene from the other parent is normal.

Other genetically inherited syndromes such as Down syndrome, Usher syndrome, Treacher Collins syndrome, Crouzon syndrome, Alport syndrome and Waardenburg syndrome include hearing loss as part of the syndrome.\textsuperscript{9}

1.2.4 Injury/trauma

Head injury, acoustic trauma, ear and brain tumors can induce a permanent sensori-neural hearing impairment. The auditory nerve is then not able to transfer signals to the brain.

1.2.5 Aging

Aging contributes substantially to damage and deterioration of the peripheral and central auditory system. Age related loss of audition is called presbyacusis. In humans, inner and outer hair cells present in the cochlea of the inner ear cannot self reconstitute, therefore a loss of or damage to these cells is irreversible and causes permanent hearing impairment. Neural loss and strial loss may also be factors. Frequency loss is progressive from high to low.

1.2.6 Exposure to prolonged or excessive noise

Exposure to high levels of noise is the most common cause of hearing loss in adults but presbycusis, which is potentiated by noise has the highest prevalence in older adults.\textsuperscript{10} 11 12 Exposure to excessive duration and intensity of noise causes progressive loss of outer and inner hair cells with damage and eventual death of the organ of Corti, ischemia of the inner ear, and increased metabolic activity leading to excessive reactive oxygen species (ROS) generation and lipid peroxidation.\textsuperscript{13} 14 15 Exposure to high level of noise such as during loud concerts or use of headphones contribute to hearing loss. Noise is also a particular concern for soldiers who are exposed to noise bombardments, hunters exposed to rifle fire, pilots and industrial workers especially in developing countries where there is more likely to be lack of available protection and the legislation to enforce it. This type of hearing loss can be either transient (called temporary threshold shift) or permanent (called permanent threshold shift). With the latter, the part of the cochlea where hair cell death occurs initially is related to the noise frequency that causes it, partly due to direct mechanical damage. The over-stimulation of hair cells also causes excessive generation of free radicals, which may continue for some time after the initial trauma.

1.2.7 Medications and other chemicals that are toxic to the ear

Certain medications are considered ototoxic as they may cause damage of hair cells in the inner ear. There are more than 200 known ototoxic medications (prescription and over-the-counter) on the market today. These include medicines used to treat serious infections, cancer and heart disease.\textsuperscript{15} 16 17 18 19 20 Hearing loss caused by these drugs is often dose-dependent and with some drugs can sometimes be reversed when the drug therapy is
discontinued (e.g. loop diuretics, quinine, salicylates). Sometimes, however, the damage is permanent.

Ototoxic medications known to cause permanent damage include all commonly used aminoglycoside antibiotics, such as gentamicin (family history may increase susceptibility), streptomycin, amikacin, kanamycin and neomycin. They all affect the vestibular system (organ of balance) as well as the cochlea although streptomycin has a greater effect on the former and neomycin acts mainly on the latter. Increased sensitivity to deafness caused by aminoglycosides can be inherited maternally. Cancer chemotherapy drugs, such as cisplatin and carboplatin can cause effects on the cochlear similar to aminoglycosides. Elevations of audiometric thresholds have been reported in some studies in 75–100% of patients treated with cisplatin. Cisplatin ototoxicity results from the production of reactive oxygen species (ROS) within the cochlea, overwhelming endogenous antioxidant mechanisms and causing irreversible free–radical-related apoptosis of cochlea outer hair cells, spiral ganglion cells, and the stria vascularis.

Hearing loss is usually bilateral and irreversible, and is particularly severe in young children with neuroblastoma, CNS malignancies, and in adults with head and neck cancers, in which the base of the skull or brain may be irradiated.

Aminoglycoside antibiotics are used in the treatment of gram-negative bacterial infections like tuberculosis; tularemia and other hospital acquired serious infections. Dose-limiting side effects include cochlear and/or vestibular toxicity and nephrotoxicity. Cochlear toxicity is primarily due to death of outer hair cells in the organ of Corti. The outer hair cells in the part of the cochlear where high frequencies are detected, die first but successively lower frequencies are then affected. Loss of inner hair cells follows after some delay.

Medications known to cause temporary damage include salicylate pain relievers (aspirin, used for pain relief and to treat heart conditions), macrolide antibiotics such as erythromycin, quinine (to treat malaria), and loop diuretics – furosemide, bumetanide or ethacrynic acid (used to treat certain heart and kidney conditions). A single dose of the last group which by itself would only cause completely reversible hearing loss, in combination with an aminoglycoside may cause rapid, profound permanent loss. Various industrial chemicals including toluene, p-xylene, ethylbenzene, styrene, trichloroethylene have been implicated in ototoxicity. The effects of solvents may be potentiated by exposure to high noise levels or noise induced hearing loss may become worse. Damage occurs particularly in the mid frequency range of hearing.

There is some evidence that excessive alcohol consumption may damage auditory centres in the brain and be ototoxic to the ear.

1.2.8 Nutritional Deficiency Causes

Iodine deficiency is common in certain parts of the world and is one of the leading causes of preventable mental handicaps worldwide, including cretinism, in which hearing loss is a feature. Maternal hypothyroidism results in congenital hypothyroidism which is fully treatable if detected soon after birth. If it is untreated the child will develop cretinism. Hypothyroidism may potentiate presbycusis in the elderly.
Update on 2004 Background Paper, BP 6.21 Hearing Loss

1.3 Diagnosis

Early diagnosis and early intervention is essential to prevent further damage and provide adaptive therapies.

1.3.1 New borns and Infants Diagnosis

In high income countries, most hospitals screen all babies’ hearing shortly after they are born. Infant screening is very important because, without such programs, the average age of detection of significant hearing loss is approximately 14 months.\textsuperscript{1,2} When hearing loss is detected late, language development is delayed, affecting a child’s ability to learn and perform in school. The screening procedures for newborns and infants are simple and painless, and can be done while the infant is resting quietly. The two common screening methods used with infants are otoacoustic emissions (OAE) and auditory brainstem response (ABR). These tools can detect hearing loss averaging 30 to 40 decibels (dB) or more in the frequency region important for speech recognition, e.g., approximately 500–4000 Hertz (Hz).\textsuperscript{27}

Otoacoustic emissions (OAEs) are sounds given off by the inner ear when the cochlea is stimulated by a sound. When sound stimulates the cochlea, the outer hair cells vibrate. The vibration produces a nearly inaudible sound that echoes back into the middle ear. The sound can be measured with a small probe inserted into the ear canal. People with normal hearing produce emissions. Those with hearing loss greater than 25–30 decibels (dB) do not produce these very soft sounds. This test can detect blockage in the outer ear canal, as well as the presence of middle ear fluid and damage to the outer hair cells in the cochlea. The high cost of the electronic instrument may preclude use in low- and middle-income countries.

1.3.2 Children and Adult Diagnosis

Hearing can be measured by partially subjective tests using a pure-tone audiometer in children aged over four years. Electrophysiological tests of hearing can provide accurate objective measurements of hearing thresholds even in unconscious subjects. Such tests include auditory brainstem evoked potentials (ABR), otoacoustic emissions (OAE) and electrocochleography (EchoG). Technical advances in these tests have allowed hearing screening for infants to become widespread.

2. What are the Epidemiological Trends for Europe and the World?

2.1 General

The WHO estimated\textsuperscript{8} that in 2008, over 360 million persons in the world have disabling hearing loss. This constitutes 5.3% of the world population, nearly 183 million adult males above 15 years old and 145 million females, which is 7.5% of the adult male population and approximately 6% of the adult female population respectively. With the ageing of the world population these numbers are expected to double by 2030-2050. Hearing impairment is considered the most prevalent impairment worldwide.
2.2 Prevalence

2.2.1 Prevalence in the world

Disabling hearing loss is unequally distributed across the world. Population based studies are rare particularly in developing countries where newborns and children are not systematically screened for hearing impairment.

Prevalence of child and adult hearing impairment appears to be substantially higher in middle- and low-income countries than in high-income countries, demonstrating the global need for attention to hearing impairment. Approximately 15% of the world’s adult population has some degree of hearing loss. Fifty per cent of those who are affected, have disabling hearing loss. Figure 6.21.2 shows the distribution of hearing loss per selected world region. Table 6.21.2 shows the estimates of disabling hearing loss in adults and children in 2012.

South and East Asia and sub-Saharan Africa remain the world regions with the highest prevalence of hearing impairment in both adults and children. This can be explained by the high rates of pre- and post-natal childhood infections such as chronic otitis media, meningitis, rubella, measles, use of ototoxic drugs and excessive noise. High prevalences in adults are due to higher rates of infections such as chronic otitis media, and meningitis, excessive noise, ototoxic drugs and ageing populations in developing countries which increase the prevalence of presbyacusis.

The lack of a comprehensive health care system, especially ear and hearing care at primary and secondary levels, lack of trained personnel at all levels, poor personal hygiene and overcrowding, poor accessibility to medications and other interventions, lack of primary, secondary and tertiary prevention interventions, lack of national planning and programmes for ear and hearing care, low resource allocation in this field also account for these high prevalence rates of hearing impairment in low and middle income countries.

Figure 6.21.2. Distribution of disabling hearing loss per selected world region

*MBD, WHO, 2012 DHL estimates; DHL adult threshold is ≥41 dB, adults of 15 years or older.

**Update on 2004 Background Paper, BP 6.21 Hearing Loss**

Table 6.21.2. Region-wise estimate of disabling hearing loss, in adults 15 years or older and children 0-14 years in millions and percentage of population (by World Bank Regions).

<table>
<thead>
<tr>
<th>Selected Regions</th>
<th>Children Both sexes</th>
<th>Adults</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>millions</td>
<td>percentage (%)</td>
<td>millions</td>
<td>percentage (%)</td>
<td>millions</td>
<td>percentage (%)</td>
</tr>
<tr>
<td>High-income</td>
<td>0.8</td>
<td>0.5%</td>
<td>19</td>
<td>4.9%</td>
<td>18</td>
<td>4.4%</td>
</tr>
<tr>
<td>Central/Eastern Europe and Central Asia</td>
<td>1.1</td>
<td>1.6%</td>
<td>14</td>
<td>9.0%</td>
<td>16</td>
<td>8.8%</td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>6.8</td>
<td>1.9%</td>
<td>17</td>
<td>7.4%</td>
<td>13</td>
<td>5.5%</td>
</tr>
<tr>
<td>Middle East and North Africa</td>
<td>1.2</td>
<td>0.9%</td>
<td>6</td>
<td>4.1%</td>
<td>4</td>
<td>2.9%</td>
</tr>
<tr>
<td>South Asia</td>
<td>12.3</td>
<td>2.4%</td>
<td>52</td>
<td>9.5%</td>
<td>36</td>
<td>7.0%</td>
</tr>
<tr>
<td>Asia Pacific</td>
<td>3.4</td>
<td>2.0%</td>
<td>19</td>
<td>8.7%</td>
<td>15</td>
<td>6.8%</td>
</tr>
<tr>
<td>Latin America and Caribbean</td>
<td>2.6</td>
<td>1.6%</td>
<td>15</td>
<td>7.6%</td>
<td>13</td>
<td>6.0%</td>
</tr>
<tr>
<td>East Asia</td>
<td>3.6</td>
<td>1.3%</td>
<td>41</td>
<td>7.4%</td>
<td>30</td>
<td>5.6%</td>
</tr>
<tr>
<td>World</td>
<td>31.9</td>
<td>1.7%</td>
<td>183</td>
<td>7.5%</td>
<td>145</td>
<td>5.9%</td>
</tr>
</tbody>
</table>

*MBD, WHO, 2011 DHL estimates, where DHL adult threshold is ≥41 dB and children threshold is ≥31 dB. Children between 0 and 14 years old and Adults 15 years or older.

Source: World Health Organisation 2012 (Countries within regions are listed in Annex 6.2.1)

Figures 6.21.3, 6.21.4 and 6.21.5 show the prevalence rate of disabling hearing impairment per world region in children, adults and elderly respectively.

**Figure 6.21.3. Prevalence of disabling hearing loss in children 0-14 years**

![Graph showing prevalence of disabling hearing loss in children 0-14 years by world region.]

*MBD, WHO, 2011 DHL estimates, children threshold is ≥31 dB (children 0 until 14 years old).

Source: Contribution from Disability Department, WHO, Geneva.
Figure 6.21.4: Prevalence of disabling hearing loss for adults of 15 years or older by selected regions.

Source: Contribution from Disability Department, WHO, Geneva.

Figure 5. Prevalence of disabling hearing loss for children, adults: 15-65 years and 65 years or older by selected regions (WHO 2011)

Source: Contribution from Disability Department, WHO, Geneva.
Hearing loss prevalence increases as age increases, reaching its highest prevalence level for adults over the age of 65 years old (from 18% in high income region to almost 50% in the South Asia region).

The prevalence increase with age is more than five times for all the regions except high-income and Central/East Europe and Central Asia region.

A recent study (2011) led by Johns Hopkins University researchers showed that nearly a fifth of all Americans aged 12 years or older have hearing loss that may make communication difficult. Researchers stated that they used the World Health Organization’s definition for hearing loss (not being able to hear sounds of 25 decibels hearing level (dB HL) or greater in the speech frequencies). However the WHO definition is 26 dB HL or greater for any level of hearing loss so the results of this study are not completely comparable with other surveys using the WHO criteria, and would produce a slightly greater prevalence. They collected data from the National Health and Nutritional Examination Surveys (NHANES) and analyzed data from all participants age 12 and over whose hearing was tested during NHANES examinations from 2001 to 2008.

Researchers found that overall, about 30 million Americans, or 12.7 per cent of the population aged 12 years or older, had hearing loss in both ears and this figure increased to 48.1 million, or 20.3 per cent, when also including people who have hearing loss in one ear. The prevalence was lower in women than men, and in black than white individuals across nearly all age decades. The findings, thought to be the first nationally representative estimate of hearing loss that used audiometric hearing testing, suggest that many more people than previously thought are affected by hearing impairment. In high income countries, studies have usually been performed on children and elderly and data on adults are scarce.

2.2.2 Prevalence in Europe

The prevalence of hearing loss in Europe is not well defined, due in part to the use of countries own classification systems for hearing impairment. As a consequence, comparison of data from several studies is difficult. Moreover, the majority of studies have focused on prevalence among people aged 65 and over and there are few detailed reports on the prevalence of hearing impairment of different grades among adults or children. There is clearly a gap in knowledge and understanding of how hearing loss affects young people that needs to be addressed.

The need for standardized procedures when collecting and reporting epidemiological data on hearing loss is essential. In this regard, WHO provided a classification on hearing impairment and recommends countries to use standard audiometric measures in population based surveys. WHO has developed a survey protocol, the WHO Ear and Hearing Disorders Survey Protocol, in order to standardize other aspects of survey methodology in addition to hearing levels. At least 12 surveys have been conducted in developing countries using this protocol.

Report from Shield (2006) found that 19 per cent of the UK men and 13 per cent of UK women above 16 years of age report that they suffer from hearing loss. Most European countries studied were higher than the usual 10% of the population often considered the
Update on 2004 Background Paper, BP 6.21 Hearing Loss

general prevalence of the impairment. Shield presents specific facts on the prevalence of hearing impairment in Europe.

- The frequency in Germany may be as high as one in five.
- In Finland, one in seven suffers from varying degrees of hearing loss.
- In Italy, one in six are suffering from some form of hearing loss.
- One in 10 has hearing loss in Denmark and Sweden.

Figure 6.21.6 shows the repartition of hearing impairment according to gender, age range and level of impairment in Western Europe in 2010. Figures are from the World Health Organization from Stevens et al, unpublished data.

Figure 6.21.6. Level of impairment repartition of hearing loss according to gender, age range in Western Europe in 2010.

<table>
<thead>
<tr>
<th>Age range</th>
<th>Population</th>
<th>Males</th>
<th>Females</th>
<th>Per cent of population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>26-40 dBHL</td>
<td>41-60 dBHL</td>
<td>61-80 dBHL</td>
</tr>
<tr>
<td>0-1 years</td>
<td>2290</td>
<td>0.8 (0.6, 1.1)</td>
<td>0.1 (0.1, 0.2)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
<tr>
<td>1-4 years</td>
<td>9061</td>
<td>0.8 (0.6, 1.2)</td>
<td>0.2 (0.1, 0.2)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
<tr>
<td>5-14 years</td>
<td>22728</td>
<td>1.0 (0.7, 1.3)</td>
<td>0.2 (0.1, 0.3)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
<tr>
<td>15-34 years</td>
<td>52683</td>
<td>2.1 (1.6, 3.0)</td>
<td>0.4 (0.3, 0.6)</td>
<td>0.1 (0.0, 0.1)</td>
</tr>
<tr>
<td>35-44 years</td>
<td>31874</td>
<td>4.7 (3.5, 6.4)</td>
<td>0.9 (0.7, 1.3)</td>
<td>0.1 (0.1, 0.2)</td>
</tr>
<tr>
<td>45-54 years</td>
<td>28887</td>
<td>8.0 (6.0, 10.7)</td>
<td>1.6 (1.2, 2.3)</td>
<td>0.2 (0.2, 0.3)</td>
</tr>
<tr>
<td>55-64 years</td>
<td>24044</td>
<td>17.7 (14.2, 22.2)</td>
<td>4.2 (3.2, 5.7)</td>
<td>0.6 (0.4, 0.8)</td>
</tr>
<tr>
<td>65-74 years</td>
<td>17829</td>
<td>31.7 (27.5, 35.8)</td>
<td>10.3 (7.9, 13.4)</td>
<td>1.6 (1.2, 2.1)</td>
</tr>
<tr>
<td>75+ years</td>
<td>12775</td>
<td>39.1 (38.1, 39.9)</td>
<td>25.0 (20.6, 29.7)</td>
<td>5.1 (3.9, 6.8)</td>
</tr>
</tbody>
</table>

Source: unpublished data (World Health Organization from Stevens et al).

People lose their hearing much earlier than in the past. This disconcerting trend is caused by the generally higher noise levels in today’s society.

In a systematic literature review, in which data were crudely averaged and interpolated, Roth et al. estimated that “roughly 55% of men and 45% of women in Europe were found to have a hearing loss of 30 dB HL or more by age 70 years.” Because of the ageing of the population in Europe these figures are expected to rise in the future.

Hearing loss prevalence estimates for 2025

According to Hear-it.com (2011); Professor Adrian Davis of the British MRC Institute of Hearing Research estimates that “the total number of people suffering from hearing loss of more than 25 dB will exceed 700 million worldwide by 2015. Davis’s statistics suggest that more than 900
All in all, the different surveys and estimates indicate that hearing loss is much more common than previously thought and that young adults and not only children and elderly people are affected.

3. What is the control Strategy?

3.1 Prevention Measures

3.1.1 Primordial Prevention

Preventing excessive exposure to noise

Noise-induced hearing loss is preventable but is often not prevented, especially in developing countries. The incidence of noise-induced hearing loss at the workplace can be reduced or eliminated through the successful application of engineering controls and hearing conservation programs. Wearing ear plugs or special earmuffs when exposed to high level of noise, reducing the volume of headphones, designing less noisy machines, lowering noise pollution from auto traffic, trains, airplanes and industry are all measures that will make a difference. Countries should enact legislation to reduce noise pollution in the workplace and enable adequate compensation, and to reduce social and other environmental noise sources. Noise pollution needs to be monitored and sanctions enforced. Building design needs to consider the acoustic environment both for normal and hard of hearing persons. Older children and young adults should be made aware that high levels of noise such as in clubs and from personal stereos can permanently damage their hearing; ear plugs should be made readily available and role models such as rock musicians should lead the way to make prevention of noise-induced hearing loss fashionable.

Preventing hearing loss due to infectious diseases

Immunisation against vaccine preventable infections especially rubella, measles, meningitis contribute to reduce the burden of hearing loss as sequelae of these diseases are known to cause irreversible hearing damage. As Morris and Leach stated (2012) “the largest gains in the prevention of severe to profound sensorineural hearing loss have come from the measles and rubella vaccines, and the protein-conjugated bacterial meningitis vaccines (targeting Hemophilus influenzae type b (Hib), pneumococcal and meningococcal disease).” Most of the mild and moderate conductive hearing loss in the world is associated with otitis media. To some extent, OM is a vaccine preventable disease. In the future, the development of otitis media vaccines (or combinations of vaccines) that reduce colonisation and protect against common respiratory bacterial and viral pathogens has the potential to dramatically reduce the frequency of mild and moderate hearing loss in young children.” The WHO’s original Expanded Programme of Immunization (EPI) started in 1974 includes measles vaccine and BCG, both of which will reduce hearing loss (the latter via
prevention of tuberculous meningitis causing hearing loss and a reduction in use of streptomycin, and ototoxic antibiotic, as second line treatment of TB. A rubella vaccine is usually used now as part of the MMR vaccine against measles, mumps, and rubella, all of which cause hearing loss, rubella as an often devastating congenital infection. It is important to note that rubella vaccination should not be introduced in a country until the coverage rate for vaccines such as measles has reached 80% to produce “herd immunity”. If rubella vaccine is commenced before this coverage is reached it may have the paradoxical effect of more women reaching child bearing age who are susceptible to rubella infection (by reducing opportunities for natural protection through infection in early childhood) and hence lead to an increase in incidence of congenital rubella syndrome. In developed countries women of child-bearing age are tested for rubella susceptibility and immunised provided they are not pregnant. Because rubella vaccine is a live vaccine there is a slight risk of teratogenicity to the foetus, so pregnant women should be vaccinated immediately after birth.

Other infections which cause hearing loss and for which research is seeking vaccines include Cytomegalovirus and HIV.

### 3.1.2 Secondary Prevention

**Screening**

Universal neonatal hearing screening programmes are expensive if fully implemented, and even in developed countries there were assessments of the cost-effectiveness and cost-benefits. The expense has precluded introduction of UNHS in most developing countries. Most developed countries and a few developing countries have implemented UNHS. Targeted neonatal screening is more common in developing countries.

Most developed countries and a few developing countries have implemented UNHS. Targeted neonatal screening is more common in developing countries. In low- and middle-income countries, due to the difficult access to health care facilities, and it is not always possible to implement such screening. Child delivery often takes place at home and health care facilities are sometimes at several hours of walking away. School screening is common in developed countries but much less common in developing countries. Screening campaigns for adults and elderly are however lacking in most countries even in developed countries and should be implemented.

### 3.1.3 Tertiary prevention

**Raising awareness of users of ototoxic medications**

Very few people, including few health care professionals, know that medications such as non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen, antibiotics such as gentamicin, and streptomycin, anti-malarial drugs such as quinine, chemotherapy agent cisplatin and some diuretic drugs and certain industrial chemicals can cause transient or permanent hearing loss. In a study published by the American Journal of Medicine researchers found that regular users of NSAIDs who were 50 or younger were 61 per cent more likely to develop hearing loss than those who were not regular users.24

Prevention involves ongoing awareness raising through information and campaigns amongst the general public, people who are hard of hearing, health care professionals,
legislators. This should be associated with an enforceable pharmaceutical licensing, distribution and clinical testing programme.

**Genetic counselling**

Other approaches to prevention include genetic counselling for some inherited causes of hearing loss, improved primary ear and hearing care including more trained personnel, better ante-natal and peri-natal care, nutritional supplementation in areas where critical nutrients are lacking (e.g. iodine), more widespread availability of affordable hearing aids and services to fit and follow up (this can be classed as tertiary prevention or rehabilitation).

**Raising awareness of decision makers**

Although hearing loss is considered to be the most prevalent chronic impairment worldwide, awareness of the problem amongst decision makers is rare because data from well-conducted, population-based epidemiological surveys are scarce, especially from developing countries. Monitoring the incidence and prevalence of hearing loss in the entire population ranging from infants to elderly would help implement appropriate measures for prevention and allocate fundings for research towards better treatment and rehabilitation.

### 3.2 Therapies

Hearing loss is not yet curable but research into auditory hair cell and nerve regeneration has made considerable progress. Hearing aids such as cochlear implants and hearing aids and other amplification systems, especially in schools, can help a person to recover partly his/her hearing and communication skills.

Audiologic rehabilitation is essential to provide appropriate training on how to best use these devices and improve hearing capacity.

**Audiologic Rehabilitation**

Audiologic rehabilitation is the process of providing training and treatment to improve hearing for those who are hearing impaired. Hearing rehabilitation services focus on adjusting to hearing loss, making the best use of hearing aids, exploring assistive devices, managing conversations and other hearing strategies, and taking charge of communication.

With infants and children, audiologic rehabilitation focuses on restoring a skill that is lost. In very young children, a skill such as talking or understanding speech may not be there in the first place and needs to be taught. The services provided will depend on each child’s individual needs and are based on the following factors: age of the child, age of onset of the hearing loss, age when hearing loss was discovered, degree of hearing loss, type of hearing loss, age of child when hearing aids were first used, commitment and capability of the parents or guardians. Early detection of hearing loss and early use of hearing aids or cochlear implants are critical for the development of speech, language, and communication skills in children with hearing loss. In fact, infants identified with a hearing loss before the onset of the critical period of language development around six months of age who received a hearing aid or cochlear implant and habilitation services have been shown years later to have language skills similar to those of children of the same age who have normal hearing. The
cost of cochlear implants is high ($40,000 in the United States) but are ranked as among the most cost effective procedures in the USA. (http://www.asha.org/about/news/tipsheets/cochlear_facts.htm) and also in other developed countries. In developing countries the cost is prohibitive for the majority of individuals with severe or profound hearing loss, and for their state health care providers. There is little data on this at present from developing countries at present. However it appears that such financial resources used in a national programme would alleviate a far larger proportion of the burden of hearing loss if allocated to strengthening of ear and hearing care services at primary and secondary levels and provision of affordable hearing aids and services, than if used for cochlear implant programmes. More research is needed on this issue.

4. What is known of the Availability, Feasibility and Sustainability of the Control Strategy?

4.1 The European Burden of Hearing Loss and cost

According to the international scientific report “Evaluation of the Social and Economic Costs of Hearing Impairment” by Shield (2006) untreated hearing loss costs Europe 213 billion euros per year.\(^{31}\) Figures of a similar order of magnitude have been estimated in the USA and Australia.\(^{35} \quad 36\)

“In the EU alone, more than 55 million people are hearing impaired, and the costs in the EU of unaided hearing impairment of all grades are estimated to 168 billion Euros per year.\(^{38}\) Based on population statistics, here are some examples of the estimated cost of untreated adult hearing loss per country:

- Germany €30 200 000 000
- France €22 400 000 000
- United Kingdom €22 000 000 000
- Italy €21 300 000 000
- Spain €16 300 000 000
- Poland €14 000 000 000
- The Netherlands €6 000 000 000

The calculations are made in accordance with the European Commission standard, setting a statistical value for 'one quality life year' at 44 000 euros, and the commonly used Health Utility Index, rating different types and degrees of diseases and sufferings/conditions in relation to a healthy person.

According to the report, a mild hearing loss costs society 2 200 euros per individual each year, a moderate hearing loss costs 6 600 euros annually per person, while a severe or profound hearing loss costs 11 000 euros per person per year. These figures do not include lost income and lost tax revenues due to unemployment or early retirement because of hearing loss.”\(^{37}\)

These figures do not include the societal costs of unemployment or early retirement caused by hearing loss. Compared to many other diseases, hearing loss more often involves the social welfare system rather than the medical care system. Therefore, medical costs, e.g. hearing aids, only account for a small percentage of the real general cost.
4.2 Feasibility and Control Strategy

Hearing devices are a viable option for hearing impaired persons to live a better quality of life but still with reduced auditory capacity. Hearing devices such as hearing assistive technologies or cochlear implants remain very expensive and many health care systems do not reimburse the cost of such devices. For most low- and middle-income countries, hearing aids and devices are just not affordable. Studies based on hearing aids production indicate that, relative to need, few hearing aids are sold in developing countries. There is likely a large unmet need for innovative interventions including affordable hearing aids and possibly cochlear implants in low- and middle-income countries. The global partnership WWHearing (Website for WWHearing: www.wwhearing.org) was set up to address the need to provide affordable, good quality hearing aids and services on a large scale in low- and middle-income countries, through its collaboration agreement with WHO. They do not currently advocate cochlear implants in developing countries, believing that the resources needed would be more effectively utilized on provision of hearing aids and thereby help much larger numbers of people with moderate or severe hearing loss.

Prevalence of disabling hearing loss for the entire population increases as the out of pocket expenditure ratio (against private expenditure on health) increases for some regions such as: high Income, sub-Saharan Africa, Latin America and Caribbean region, and South Asia region as shown in Figure 6.21.6.

Despite their intensive attempts, Stevens et al. were unable to address hearing aid use in developing countries. They stated in their discussion "We did not have sufficient data to estimate hearing aid use in developing countries, but suspect that coverage is small to negligible: one study in Brazil did not identify anyone who used a hearing aid, and combining our data with data on hearing aid production indicates that, relative to need, few hearing aids are sold in developing countries. A primary obstacle to hearing aid provision in developing countries is their cost. There is likely a large unmet need for innovative interventions including low-cost hearing aids in developing countries." Since the burden of hearing loss is much greater in developing countries, this is where the focus of action should be, from a public health point of view.
Figure 6.21.6. Prevalence of Disabling Hearing Loss for all population versus average out of pocket expenditure ratio as percentage of private expenditure on health for selected regions. (WHO 2011)

5. Why does the Disease Burden Persist?

5.1 Lack of awareness of the problem

Although hearing loss is the most important cause of disability worldwide, there is a lack of awareness of the problem in all sectors of the population including health care professionals as well as a lack of health educational programmes for prevention and detection (in addition to the lack of investment by most developing countries in programmes, infrastructure and trained personnel). Because hearing loss is an invisible disability, and most people and governments are not aware of the large size of the problem, children with hearing loss are not discovered and may be mistaken to have intellectual disabilities in school. In adults, hearing loss more often evokes irritation than sympathy. In health care, there is a lack of national programmes to address hearing loss, especially in developing countries where the burden and need is greatest, and a lack of investment in training, equipment, career structures and infrastructure.
5.2 Poor Diagnosis

Diagnosis for hearing loss is often neglected. In most high income countries, only newborns infants and school children are screened systematically, but not young adults and elderly. In high income countries, people with moderate hearing loss delay diagnosis because they are afraid to be stigmatized.

In low- and middle-income countries, screening of newborns and children is sparse and adults are not diagnosed for hearing impairment due to difficulty of access to medical facilities, and lack of trained personnel and equipment. Moreover, cochlear implants remain too expensive and not affordable. Studies based on hearing aid production indicates that, relative to need, few hearing aids are sold in developing countries. There is likely a large unmet need for innovative interventions including affordable hearing aids in low and middle income countries.37 38

5.3 A lack of epidemiological data

There is a lack of epidemiological data worldwide, especially from population-based, random sample surveys using standardised methods in developing countries. Only a few countries, even in Europe, have implemented programmes of detection to cover the entire population. Hearing loss remains poorly reported and many countries and surveys use different classification systems, making it difficult to compare data between countries. There is a need for standardized procedures when collecting and reporting epidemiological data on hearing loss, such as the WHO Ear and Hearing Disorders Survey Protocol.

5.4 Poor living conditions and lack of vaccination coverage

In developing countries, disease burden of hearing loss persists because of the poor health care systems, especially at the primary level of health care, absence or lack of vaccination coverage for children and mothers, poor personal hygiene factors and poor living conditions as well as cultural issues such as consanguineous marriage that favors the transmission of genetically inherited forms of hearing impairment. It is estimated that 50% of these hearing losses could be prevented by primary, secondary and tertiary means, and the lack of programmes and poor availability and cost of health care in these developing nations often makes preventive interventions unavailable and treatment expensive.1 Cochlear implants remain too expensive and are not affordable.39

5.5 Underuse of hearing devices

Hearing aids can be used effectively for patients with moderate to severe hearing loss, however, only one out of five people who could benefit from a hearing aid actually wears one.39 In high income countries, because of stigmatization and as hearing loss is negatively perceived, the usage of these devices is low and only occurs when a person realizes that he/she needs help from a professional or when their hearing is very poor. Major barriers to improve hearing in older adults include lack of recognition of hearing loss, perception that hearing loss is a normal part of aging or is not amenable to treatment, and patient non-adherence with hearing aids because of stigma, cost, inconvenience, disappointing initial results, or other factors.22, 28, 33 40 41
Update on 2004 Background Paper, BP 6.21 Hearing Loss

While the development of the cochlear implant has been remarkable, the prognosis for those individuals receiving an implant is still variable and, even with the best outcomes, normal hearing is not restored. Therefore patients with severe hearing loss would welcome alternative strategies, and in particular, medical treatments for hearing rehabilitation.

This may not apply to persons with profound or complete hearing loss, some of whom regard themselves as a distinct cultural and linguistic group with their own language (sign language) and rights similar to other minorities.42

5.6 Exposure to noise

Urbanisation and modern living life style has generated a noisier environment. Loud concerts, use of headphones, road traffic, are all likely to contribute to the loss of audition in many young adults.

Exposure to excessive noise is the major avoidable cause of permanent hearing impairment worldwide according the World Health Organization (WHO).2 Occupational noise and urban, environmental noise are increasing risk factors for hearing impairment worldwide, including in developing countries.

WHO recommends that countries should implement National Programmes for the Prevention of noise-induced hearing loss, integrated with Primary Health Care, and including elements on health promotion, and measures to reduce noise sources and introduce properly enforced legislation and effective hearing conservation.2, 41

5.7 Aging of the population

Aging leads to deterioration of hearing function in the majority of elderly persons and is one of the major key factor for hearing loss. As the world population ages people affected by hearing loss are expected to rise significantly. According to the World Health Organization “In 2010, an estimated 524 million people were aged 65 or older, 8% of the world’s population. By 2050, this number is expected to nearly triple to about 1.5 billion, representing 16% of the world population. Although more developed countries have the oldest population profiles, the vast majority of older people, and the most rapidly aging of the world’s populations, are in less developed countries. Between 2010 and 2050 the number of older people in less developed countries is projected to increase more than 250 per cent, compared with a 71 per cent increase in developed countries.” (From the WHO Global Health and Aging Report 2012.)

5.8 Gaps of research into pharmacological interventions

As a result of a lack of awareness of decision makers, very limited research funding has been allocated towards search for pharmaceutical compounds. The search for pharmaceutical agents to prevent or treat hearing loss has been for many years under-investigated. New research and clinical trials towards a possible treatment have started to emerge in the past few years.
6. Past/Current Research into Pharmaceutical Interventions for this Condition

Based on the successful results from animal studies, several clinical trials have been launched to investigate the effects of a wide variety of compounds in preventing hearing loss in humans. Most of these studies are focused on patients exposed to ototoxic medications such as cisplatin or aminoglycoside therapies or exposed to high level of noise. The different strategies such as the use of antioxidants, anti-inflammatory agents, anti-apoptotic factors as well as RNA silencing or use of stem cells to restore hair cell function within the cochlea are described below.\(^4\)

Ototoxicity is an alteration caused by medications that compromises the auditory and vestibular functions. Cisplatin is a potent agent used for the treatment of cancer in both adults and children although it has several side effects. Current opinion is that cisplatin ototoxicity occurs due to alterations in the antioxidant system of the outer hair cells (OHC) of the cochlea. The distortion-product otoacoustic emissions (DPOAE) has been showed to be a sensitive test for diagnosis of OHC injury and has been used for monitoring treatment with ototoxic drugs.

6.1 Antioxidants and ROS scavengers

6.1.1 Sodium thiosulfate (STS)

Sodium thiosulfate is an inactive ingredient contained in sulfacetamide ophthalmic solution which is used routinely as an otic solution delivered to the middle ear space. Sodium thiosulfate is a free–radical-scavenging thiol agent.\(^4\)

In vitro, STS acts in several ways: it directly inactivates cisplatin by the covalent binding of cisplatin to its thiol moiety to form an inactive complex, it scavenges cisplatin-related reactive oxygen species, and it may concentrate in the perilymph or endolymph, further inactivating cisplatin in the inner ear.\(^4\)

A large Clinical Study with 250 participants led by the German GPOH, the Japanese Study Group for Pediatric Liver Tumors, and several USA centers, began the first large randomized trial of STS (SIOPEL 6) in 2007 to reduce ototoxicity in children with hepatoblastoma.\(^2\) In this trial, sodium thiosulfate is given intravenously and there are concerns that it could potentially affect the antitumorigenic effect of cisplatin by interacting in the blood and inactivating it.

In a parallel study, the Children’s Oncology Group launched a randomized phase III clinical trial NCT00716976 to evaluate the efficacy of STS for preventing cisplatin-related hearing loss in newly diagnosed children with hepatoblastoma, germ cell tumors, medulloblastoma, and osteosarcoma.\(^4\)\(^7\)

The primary objective of clinical trial NCT00716976 “Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy” is to “compare the efficacy of sodium thiosulfate versus observation in preventing hearing loss in young patients receiving cisplatin
for the treatment of newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.”

Two clinical trials are currently in phase III and are recruiting participants.

The primary outcome of clinical trial NCT01369641 “The Effect of sodium thiosulfate (STS) Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy” is “to assess the efficacy of intratympanic sodium thiosulfate (STS) on reducing the degree or incidence of hearing loss in patients receiving systemic cisplatin therapy using puretone and speech audiometry, and distortion product otoacoustic emissions (DPOAE). Hearing will be assessed prior to any initiation of cisplatin therapy, again at three weeks, six weeks, 12 weeks, and every six months thereafter for up to one year.” The trial is currently recruiting patients and final data collection date for primary outcome measure is expected for 2015.

The hypothesis of this study is that local administration of sodium thiosulfate (STS) will result in improved hearing compared to ears not receiving the study drug in patients receiving systemic cisplatin therapy.

Clinical trial NCT00652132 “Cisplatin With or Without Sodium Thiosulfate (STS) in Treating Young Patients With Stage I, Stage II, or Stage III Childhood Liver Cancer”, was sponsored by Children’s Cancer and Leukaemia Group. This randomized phase III trial is studying how well sodium thiosulfate (STS) works to decrease hearing loss caused by cisplatin in treating young patients with stage I, stage II, or stage III childhood liver cancer as well as carefully monitor any potential impact of STS on response to cisplatin and survival.

Results are expected in the following years. In this trials, sodium thiosulfate is given intravenously and there are concerns that it could potentially affect the antitumorigenic effect of cisplatin by interacting in the blood and inactivating it. New ways of injections of STS in the inner ear will certainly help circumvent this potential effect. Cisplatin is an important anticancer drug in children, potentially limited by its ototoxic effect which is particularly serious in children. Thus research on minimising or eliminating this side effect would be important for the children’s oncology field although this would not make a large reduction to the overall burden of hearing loss. However research in this may have spin-off in protecting against other causes of ototoxicity. This would increase its prioritization from a public health point of view.

### 6.1.2 Alpha Lipoic Acid

Alpha lipoic acid is a fatty acid found naturally inside every cell. As an antioxidant it protects against free-radical damage, supports nerve system function, and plays an essential role in generating mitochondria in the hair cells of the inner ear. Animal models have shown that alpha lipoic acid protected tested animals from age, noise and cisplatin induced ototoxicity.\(^{48-50}\)

Phase II and III clinical trials (NCT00477607) Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment with Cisplatin were completed in 2011.

In this trial “patients received oral alpha-lipoic acid supplement or placebo once a day beginning one week before the start of cisplatin treatment and continuing for up to one month after the completion of
cisplatin. During cisplatin treatment, patients discontinue supplement one day prior to the cisplatin treatment and resume daily supplements two days post treatment.” Results have not been posted yet.

6.1.3 N-acetylcysteine

Animal studies have shown that N-acetylcysteine can protect the inner ear against damage.\textsuperscript{38} It is not known whether the drug has similar effects in humans. This compound is currently being tested in several clinical trials.

The clinical trial (NCT00552786) Antioxidation Medication for Noise-induced Hearing Loss, sponsored by the National Taiwan University Hospital, showed that N-acetylcysteine prevented temporary daily threshold shifts at high noise frequencies but did not seem to affect the temporary threshold shift at low frequencies.\textsuperscript{43}

The clinical trial (NCT01271088) Protective Effect of N-acetylcysteine Against From Ototoxicity, sponsored by TC Erciyes University, has been completed and no results have been posted so far.\textsuperscript{43}

The clinical trial (NCT01131468) on Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-acetylcysteine has been completed in 2010 but no results have been posted so far.\textsuperscript{43}

The clinical trial (NCT00525551) on the Efficacy of N-acetylcysteine in Patients Undergoing Surgery for Otosclerosis, sponsored by Karolinska Institutet and AstraZeneca, is currently recruiting participants. This study will assess the efficacy of N-acetylcysteine in patients undergoing surgery for otosclerosis.\textsuperscript{43}

6.1.4 Ginkgo Biloba

Ginkgo biloba is a potent antioxidant and ROS scavenger that has been shown to be an effective otoprotectant in sudden hearing loss and cisplatin ototoxicity in animal models.\textsuperscript{51} A clinical trial (NCT01139281) on “The Protective Effect of Ginkgo Biloba Extract (GBE761) on Cisplatin-induced Ototoxicity in Humans” has been completed. Side effects have been reported such as bleeding, gastrointestinal disturbances, headaches, dizziness, and allergic skin reactions. Results concerning the protective effect of ginkgo biloba extract (GBE761) have not been posted so far.\textsuperscript{52}

6.1.5 Dietary supplements: Vitamins and minerals

Antioxidant therapy has been shown to be effective in animal studies. Vitamins that act as ROS scavengers (such as vitamins A, C, and E) act in synergy with minerals like magnesium (Mg) to effectively prevent noise-induced damage to the inner ear.\textsuperscript{53}

Results from Phase II Clinical trial (NCT00808470) “Micronutrients to Prevent Noise-induced Hearing Loss”, sponsored by University of Brasilia, are expected. Pharmaceutical interventions against noise-induced hearing loss would be a public health priority since this is a widespread cause which can be prevented by primary prevention but has as yet no therapeutic interventions that can prevent or treat it.
6.2. Anti-inflammatory agents

6.2.1 Salicylate/Aspirin

Aspirin has been shown to be otoprotective in both cisplatin as well as noise induced ototoxicity in animal experiments.\(^\text{54}\) The permanent threshold shift (PTS) in mice pretreated with salicylic acid just before the noise exposure was significantly smaller than that in mice exposed to the same noise without salicylic acid. The PTS in the latter was not significantly different from that in mice who received the drug just after the noise. Thus treatment with salicylates, just before noise exposure, may protect the ear from a noise-induced hearing loss.\(^\text{55, 56}\)

Clinical trial: “Use of Aspirin to alleviate aminoglycoside ototoxicity : A prospective, randomized, double-blind placebo-controlled clinical trial of aspirin administration to patients receiving gentamicin” showed a slight protective effect of aspirin versus placebo on incidence of hearing loss. Side effects such as gastric symptoms occurred more frequently in the aspirin-treated group, and three patients had to be discontinued from the study because of gastric bleeding.\(^\text{43}\)

Results from another clinical trial NCT00578760 “Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?”, sponsored by the University Health Network in Toronto are also expected.

6.2.2 Steroids

Sudden hearing loss can be treated with the use of corticosteroids although there are few clinical trials and none that clearly demonstrate their effectiveness. However almost all physicians use them since there are few other options for treatment for idiopathic sudden hearing loss in which there is any evidence of effectiveness. Steroids, provided they are not contraindicated, are usually given as an oral course for 10-14 days and the dose then tapered. The problems of oral steroids that may occur such as of weight gain, insomnia, and an increase in blood sugar are unlikely to be difficult to manage if the treatment is not prolonged further and the correct dosage used.\(^\text{57}\) Audiologists have found that these side effects can be avoided when steroids are injected into the middle ear. Recent guidelines state that the intratympanic route should be used if systemic steroids are contraindicated or the side effects thought to be difficult to manage. However there are also risks with this procedure. Studies from animals experiments showed that corticosteroids can attenuate the cisplatin and aminoglycoside induced generation of ROS in the cochlea, and thus prevent hearing loss.\(^\text{58}\)

Use of steroids for treating hearing loss is a very active field of investigation at present.

A Cochrane Review on the use of steroids for treating hearing loss showed that “corticosteroids significantly reduced hearing loss and neurological sequelae, but did not reduce overall mortality. Data support the use of corticosteroids in patients with bacterial meningitis in high-income countries. We found no beneficial effect in low-income countries.” But an unproven effectiveness, or lack thereof, of steroids in the treatment of idiopathic sudden sensorineural hearing loss as well as “no evidence of benefit from treatment of OME with topical intranasal steroids, alone or in combination with an antibiotic, either at short or longer-term follow up.”
Update on 2004 Background Paper, BP 6.21 Hearing Loss

See Cochrane summary table in Annex 6.21.3. Other specific therapies are needed, such as adequate-doses of antibiotics for meningococcal meningitis which is epidemic in Africa and also quite common elsewhere.

Several clinical trials are currently recruiting participants:

Clinical trial NCT01186185 “Fludrocortisone for Sudden Hearing Loss”, sponsored by Oregon Health and Science University.43

Brief summary: The standard of care treatment of sudden hearing loss uses a type of steroid called glucocorticoid. Examples of glucocorticoids are prednisone, methylprednisolone and dexamethasone. Not everybody recovers hearing with glucocorticoid treatment. Fludrocortisone is a different type of steroid called mineralocorticoid. Unlike glucocorticoids, which work by reducing inflammation, mineralocorticoids work by changing salt and fluid balance. In animal studies, fludrocortisone is at least as effective as glucocorticoid in preserving hearing. Fludrocortisone is not approved for the treatment of sudden hearing loss. The purpose of this study is to test whether fludrocortisone can treat sudden hearing loss.

Clinical trial NCT00802529 “Transtympanic Gentamicin versus Steroids in Refractory Meniere’s Disease”, sponsored by Imperial College London.43

The purpose of this trial is to compare transtympanic steroids against the standard treatment (transtympanic gentamicin) in refractory unilateral Meniere disease.

Clinical trial NCT01412177 “OTO-104 for the Treatment of Meniere’s Disease”, sponsored by Otonomy, Inc.43

The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere disease.

6.2.3  TNF-α inhibitors

Pro-inflammatory cytokines like TNF-α, IL-6, IL-1β have been shown to be released by the organ of Corti on cisplatin exposure, aging and sudden sensorineural hearing loss (SSHL).59 Acute noise-induced inner ear hearing loss is characterized by microcirculatory disturbance in the stria vascularis. In addition to the immunomodulatory effect, inhibition of TNF-α activity might prevent vasoconstriction of the spiral modiolar artery by inactivation of sphingokinase-1 in the S1P/S1P2 signaling system in vascular smooth muscle cells as well as reduce downregulation of nitric oxide-mediated vasodilation. Therefore, early treatment with TNF-α-inhibitors might prevent hearing impairment by restoring cochlear blood flow. Studies showed that the use of TNF-α neutralizing antibody infliximab or etanercept either by intraperitoneal or subcutaneous route of administration provided complete protection from cisplatin ototoxicity.40, 41 TNF-α antibody Enbrel® (Amgen and Pfizer Inc) is already FDA and EMA approved for autoimmune disorders including rheumatoid arthritis.

Clinical trial NCT01526174 “Intratympanic Injection for Autoimmune Inner Ear Disease (AIED)”, sponsored by Janssen Services, LLC and House Research Institute, is currently recruiting participants.43 AIED is a rare disease with a prevalence of less than 1/1000 of the population.
Summary: The investigators plan to conduct an open-label intratympanic injection proof-of-concept trial of golimumab, a TNF-alpha inhibitor, assessing for hearing loss progression in patients with autoimmune inner ear disease (AIED). This specific aim will be achieved using a two-arm approach. First, the investigators propose to dose three individual subjects with a single intratympanic injection of golimumab and follow each for 30 days, closely examining them for adverse events. If there are no serious adverse events, with FDA approval, the investigators propose to dose 14 subjects, each with four intratympanic injections of golimumab. Results are expected for August 2014.

6.3 Anti-apoptotic agents

High level of noise exposure as well as ototoxic medications have been shown to induce the stress leading to death apoptotic pathways of the outer hair cells of the inner ear. Inhibitors of signaling molecules involved in the apoptotic pathway such as mitogen-activated protein kinase (MAPK)/c-Jun-N terminal kinase (JNK) by transtympanic injections have been successful in conservation of hearing in animals. Clinical trials in humans have been performed to evaluate the potentiality of these inhibitors.60-64

Results of the study Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II showed that AM-111 is therapeutically effective in noise induced hearing loss.42 A larger study with more participants is required to test the efficacy of AM-111 in noise induced hearing loss. However, because of the high incidence of side effects, this drug may not prove tolerable in patients with noise trauma.65

Summary: In hearing loss induced by cisplatin and aminoglycosides therapies exist which appear to be effective in humans. More research is needed to identify which patients benefit most and which are the most effective therapies. This is particularly important for patients treated for multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in which hearing loss is common.

6.4 New Promising drug candidates from animal studies

6.4.1 RNA interference

Both microRNA (miRNA) and short interfering RNA (siRNA) are promising tools for gene delivery within the cochlea. The anatomical isolation of the cochlea reduces the risk of degradation of siRNA and miRNA by contact with blood and degradating enzymes. Recent progress in optimization of delivery techniques within the cochlear render cochlear injection possible. Gene transfer therapy offers the possibility of arresting, reversing and even curing hearing loss/deafness from some causes. Research currently in noise-induced and ototoxic hearing loss. Ultimately the target would be in persons with inherited forms of hearing loss.66

This is major cause, and recognised as one of the three commonest causes of hearing loss by WHO, the other two being presbyacusis and otitis media.

Studies have at present been performed on animal models only and results are promising. Silencing of genes such as transient receptor potential vanilloid 1 (TRPV1), NOX3, cochlear specific NADPH oxidase enzyme and the signal transducers and activators of transcription 1
siRNA and miRNA present exciting possibilities for the prevention of hearing loss and otoprotection as they are gene specific and thus are not likely to compromise the chemotherapeutic activity of cisplatin.

### 6.4.2 Nanotechnology for drug administration to the cochlea

Lipid nanocapsules are potential vectors for drug delivery into the spiral ganglion cells, nerve fibers, hair cells, and spiral ligament. Tested in animal models, they have shown to distribute throughout the inner ear without any signs of inflammation.

### 6.4.3 D-methionine

D-methionine, a sulfur-containing amino acid was shown to effectively reduce cisplatin ototoxicity, noise induced hearing loss and increase the levels of antioxidant enzymes in animal models. Concern remains whether systemic administration of D-methionine would potentially inhibit the anti-tumor efficacy of cisplatin.

The phase III clinical trial NCT01345474 “D-methionine to reduce Noise-Induced Hearing Loss (NIHL)”, sponsored by the Department of Defense and Southern Illinois University, is currently recruiting participants.

“The goal of the study is to develop a safe, oral pharmacological agent to augment physical hearing protectors for noise exposures that exceed the protective capabilities of ear plugs and/or muffs. The study population is a cohort of Drill Sergeant (DS) instructor trainees during and 22 days after their 11 day weapons training. The primary objective of this study is to determine the efficacy of D-Met in preventing NIHL or reducing tinnitus secondary to a minimum of 500 rounds of M-16 weapons training occurring over an 11 day period.” Results are expected in 2017.

### 6.4.4 Resveratrol

Resveratrol is the active polyphenol found in the skin of red grapes and is thus abundant in red wine. Resveratrol ingestion for three weeks prior to noise exposure and continued post noise exposure period of four more weeks showed significant preservation of hearing in rats.

### 6.4.5 Neurotrophic factors

T-817MA (1-[3-[2-(1-benzothiophen-5-yl) ethoxy] propyl]-3-azetidinol maleate) protected the cochlea functionally and morphologically during noise induced hearing loss in guinea pigs.

### 6.4.6 Caspase Inhibitors

The caspase family of cysteine proteases plays a key role in apoptosis. When administered by intracochlear perfusion inhibitors of caspases 3 and caspases 9 showed significant protection.
from cisplatin ototoxicity in guinea pigs. A number of interesting chemicals are being investigated and are receiving more attention because of the huge problem of hearing loss. However it is difficult to recommend any for further research funding until further results are known.

6.4.7 Stem cell transplantation

One very exciting and promising field of research for restoring hearing function is the use of stem cells. The recent emergence of stem cell technology has the potential to open new approaches for hair cell and auditory nerve regeneration.

In contrast with mammals, birds and all other vertebrates have been shown to add and/or regenerate hair cells and auditory function throughout their lives. These regenerated hair cells arise from a population of stem/progenitor cells that reside within the sensory epithelia. Over the past two decades, research has been undertaken to better understand of the genes and cellular interactions that regulate different aspects of inner ear morphogenesis and hair cell regeneration in model systems such as chicken and zebrafish.

The stem cells can be obtained from many different adult stem cell types, such as fibroblasts, which offer several advantages as they can be obtained from any patient and transplanted back to the same patients without immunological reaction or ethical concern.

Exciting new research has shown that mouse embryonic stem and induced pluripotent stem cells could be converted into otic progenitor cells. After several treatment, these cells could aggregate into epithelial clusters and following mechanical stimulation, bundle-bearing cells in these clusters generated currents resembling transduction currents from immature hair cells. Even though the use of stem cells to repair cochlear injury is relatively new they appear to be a very promising possibility for the treatment of hearing loss induced by noise, ageing or ototoxic drugs. These three causes comprise a major part of the burden of hearing loss, so if this approach were successful could have a large public health effect of hearing impairment. Further research should be supported.

Clinical trials based on the use of stem cells for the treatment of hearing loss are expected to be launched in the future.

6.4.8 Targeted Neural Stimulation

Stanford researchers are studying ways to bypass the hair cells and directly stimulate auditory nerve cells by using focused laser energy to restore hearing. According to the researchers “Using laser light to precisely target a single auditory nerve cell may have the potential to restore hearing and speech discrimination or a wide range of frequencies. The technology could be integrated into a hearing aid that could be positioned outside of the cochlea, eliminating the risk of additional hearing loss or meningitis.”

This approach sounds far-fetched at present but if it could work would eliminate many of the problems associated with cochlear implants, such as invasiveness of the procedure and the potential complications, as mentioned. This technology research should be watched but not yet supported until some preliminary results are available. The Stanford group conducting
this research, are conducting other ground-breaking research on Gene therapy, stem cell therapy and molecular therapy.  

7. What is the Current “Pipeline” of Products that Are to Be Used for this Particular Condition?

At present very few medicines are being used to treat hearing loss. Steroids and antioxidants can be prescribed to palliate sudden sensory hearing loss (as discussed previously). Apart from this particular case, no medicines are currently available at present to treat loss of hearing. New agents that could potentially restore hearing capacity after cellular damage or prevent hearing loss are currently in development. Some products can be used to prevent predictable hearing loss.

Several devices such as hearing aids, cochlear implants, middle ear implant can be used to amplify sounds or help people hear better. Alternatively, when none of these devices can be used, sign language and speech reading remain an alternative to help people to communicate and lead a life as normal as possible.

In public health terms, the greatest burden of hearing loss is in less developed countries (80% of disabling hearing loss is in LMIC, two thirds in developing countries). The majority of these countries lack even basic programmes against hearing loss and the personnel and infrastructure to prevent hearing loss or provide rehabilitation with affordable hearing aids and services. The knowledge and technology is available now, what is lacking is the awareness, political will leading to training for personnel, infrastructure and equipment to provide them effectively. This should include strengthening ear and hearing care at the primary level of health care, especially targeting acute and chronic otitis media, the largest cause of mild & moderate hearing loss in children in developing countries. This would make the largest difference to the problem and implementation could start immediately. In addition, the EC could support promising cutting edge research such as use of anti-oxidants and other drugs and their delivery to the cochlea, gene therapy and stem cell research.

7.1 Extended Wear Hearing Aids

These aids are devices that are nonsurgically placed in the ear canal by an audiologist. These are expensive and special training is needed to fit them. They are worn up to several months at a time without removal. The devices are made of soft material designed to fit the curves of the ear. They are worn continuously and then replaced with a new device. They are very useful for active individuals because their design protects against moisture and earwax, and they can be worn while exercising, showering, etc.

The majority of hearing aids sold today are canal hearing aids and in-the-ear hearing aids. The majority of hearing aids are sold today in high income countries despite the majority of the burden being in low- and middle-income countries. Fewer than one in 40 of the people in the developing world who need a hearing aid actually have one. There is a massive unmet need in LMICs. BTE hearing aids would be suitable for use in these countries (less expensive, easier to fit and follow-up, possible problem with stigma). The behind-the-ear (BTE) hearing
aid is the most commonly recommended aid for infants and young children (see below for explanation); however, many adults now wear the open fit style of BTE.

There are also special hearing aids built to handle very specific types of hearing loss. For example, a bone conduction aid uses a headband and a bone vibrator for individuals who have no ear canal or outer ear. These devices bypass the outer and middle ear and directly stimulate the cochlea. A relatively new innovation is the osseo-integrated hearing aid (bone anchored), which is implanted in the skull. This device has three parts: a titanium implant, an external abutment, and a detachable sound processor.

### 7.2 Cochlear Implants

A cochlear implant is a device that provides direct electrical stimulation to the auditory nerve in the inner ear. Children and adults with a severe to profound hearing loss who cannot be helped with hearing aids may be helped with cochlear implants. This type of hearing loss is sensorineural, which means there is damage to the hair cells in the cochlea. Because of this damage, sound cannot reach the auditory nerve. With a cochlear implant, the damaged hair cells are bypassed, and the auditory nerve is stimulated directly.

The benefits from a cochlear implant depend on many factors, such as the age of the patient, whether the hearing loss was present before or after the patient developed language skills and the motivation of the patient.

Cochlear implants have external (outside) parts and internal (surgically implanted) parts that work together to allow the user to perceive sound.

The external parts include a microphone, a speech processor, and a transmitter. The microphone picks up sounds and sends them to the speech processor. The speech processor is a computer that analyzes and digitizes the sound signals and sends them to a transmitter worn on the head just behind the ear. The transmitter sends the coded signals to an implanted receiver just under the skin.

The internal (implanted) parts include a receiver and electrodes. The receiver is just under the skin behind the ear. The receiver takes the coded electrical signals from the transmitter and delivers them to the array of electrodes that have been surgically inserted in the cochlea. The electrodes stimulate the fibers of the auditory nerve, and sound sensations are perceived.

Both children and adults receive extensive rehabilitation services from audiologists, speech-language pathologists, teachers, and counsellors as they learn to listen, improve speech, use speechreading, and handle communication. They are taught how to use the implant and how to respond to the sounds they are receiving. For those who have heard before, sounds through the cochlear implant may seem unnatural at first. Those who have never heard before must be taught what the sounds are.

In developing countries the cost [of cochlear implants] is prohibitive for the majority of individuals with severe or profound hearing loss, and for their state health care providers. There is little data on this at present from developing countries at present. However it appears that such financial resources used in a national programme would alleviate a far
larger proportion of the burden of hearing loss if allocated to strengthening of ear and hearing care services at primary and secondary levels and provision of affordable hearing aids and services, than if used for cochlear implant programmes. More research is needed on this issue. Some centres are trying to develop an “affordable cochlear implant” but the cost is still far too high for most people in developing countries.

7.3 Middle Ear Implants

These hearing systems are implanted in the space behind the eardrum that mechanically vibrate the middle ear structures. This device has two parts: an external portion and an implanted portion. There are also hearing aids called CROS (contralateral routing of signal) aids that route sounds coming to one ear over to the other ear. These devices are for use by individuals who have no hearing in one ear. In special cases, hearing aids can be built into glasses for individuals who need that type of fitting. Given the many innovations, there are hearing aids available that can accommodate virtually any kind of hearing loss, except when it is very severe or profound or the wearer is unable to tolerate or manage a hearing aid.

7.4 Sign Language

When the infant or young child is totally deaf and there are no alternative for the use of hearing assistive technology or cochlear implants, sign language and speechreading can be taught. Speechreading training provides formal instruction in how speech sounds are made, which sounds look alike on the lips. Learning which words have the same mouth movement but very different meaning can be incredibly useful in increasing understanding of conversations. People can also gain a great deal of helpful information from following other visual clues like facial expression, gestures, body movement, and body language. Sign language and speechreading will allow the child and future adult to communicate, have an education and lead a well-adjusted life.

8. What is the Current Status of Institutions and Human Resources Available to Address the ear disease and hearing impairment and disability?

Numerous hearing loss & deaf associations and organisations in Europe, the USA and across the world work to inform patients, provide counselling, support people affected by hearing loss. Research has been performed up to now only in academic settings.

8.1 Public Fundings

8.1.1 European Sources of Funding

Member states in the European Union are implementing The Directive on Environmental Noise in order to protect the European citizens against noise encroaching on their homes.

The Directive on Environmental Noise, passed by the European Parliament in June 2002 obliges the member states to map out noise patterns in heavily populated areas. These
measures are intended to protect the European citizens against noise surrounding their homes. Authorities must educate the population about noise and develop action plans to lower noise pollution from auto-traffic, trains, airplanes and industry.83

The Institute of Health and Consumer Protection, one of the seven scientific institutes of the European Commission's Joint Research Centre (JRC), is providing technical support for the implementation of these directives. Its activities focuses on the development and harmonization of noise assessment methods, based on state-of-the-art scientific and technical know-how, in collaboration with experts nominated by the EU Member States, the European Environmental Agency (EEA), the European Aviation Safety Agency, and the World Health Organization in Europe. This process, which is known as CNOSSOS-EU, is coordinated by the JRC-IHCP. In March 2011, a joint WHO-JRC "Report: Burden of disease from environmental noise. Quantification of healthy life years lost in Europe", reviewed the evidence of health effects consequent to noise exposure and estimated the burden of disease in western European countries, providing guidance on how best to quantify risks from environmental noise. In September 2012, a JRC Reference Report "Common Noise Assessment Methods in Europe (CNOSSOS-EU)" described the common framework required for the implementation of the 'Environmental Noise' directive.84

8.1.2 Initiatives from the World Health Organization (WHO)

In 1997, the Programme for the Prevention of Deafness and Hearing Impairment of the World Health Organization, organised a meeting of experts from developed and developing countries in order, not only to assess research needs, but also to seek methods for prevention. Occupational setting as well as environmental and leisure settings are recognised as sources of excessive noise and significant risk for hearing loss.

Experts have stressed on the need for the development or improvement of prevention initiatives, for an increase in the awareness of risk from noise, improvement of the training of health personnel, and gathering of epidemiological data.85

Other sources of funding include bilateral aid from various governments, the work and support of various NGOs, notably CBM which is the largest funder of programmes for hearing loss in the developing world and various foundations that have funded hearing loss research and programmes.

8.2 Private Fundings

At present, very few companies are starting to develop potential pharmacological treatments for hearing loss.

In June 2011, Sanofi (EURONEXT: SAN and NYSE: SNY) announced a two-year research collaboration with the biopharmaceutical company Audion Therapeutics (Audion) to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach.

"This collaborative research will utilize technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory, one of the world’s largest basic research facilities dedicated to the study of hearing and deafness, by investigator and Audion co-founder Dr Albert Edge, who has strong expertise in stem cells and inner ear biology. Audion licensed Dr Edge’s
9. **Gaps between current research and potential research issues which could make a difference**

Recent studies have demonstrated the efficacy of a wide variety of protective agents against hearing loss and cochlear damage from noise and ototoxic injury from aminoglycosides and cisplatin. Most of these investigations were carried out in vitro or in rodent models. Several clinical trials have been initiated to study the effects of these agents in patients.

The key findings in research done in this field to date are that a wide variety of potential protective agents have been reported against noise and ototoxic drugs in animal models such as rat, guinea pig, gerbil, or mouse. There have been reports that a wide range of drugs appear to protect against hearing loss from ototoxic insults from cisplatin, aminoglycoside antibiotics and noise. However, most experimental studies have demonstrated only partial protection. **Positive results from ongoing trials combined with additional laboratory tests should accelerate the time from the bench to clinical treatment.**

There are challenges in delivery of protective agents to the cochlea. Some drugs or genes have been delivered by intracochlear perfusion, which is too invasive for application to patients. Very few investigations have used the oral route of administration. Very little information on side effects has been reported, including the potential for interference with desired therapeutic effects of chemotherapy or antimicrobial therapy. **Delivery should be noninvasive or only minimally invasive.** Oral delivery would be ideal if the protective agent has the desired pharmacokinetic characteristics, however, intravenous or subcutaneous injection would also be acceptable.

**The discovery of new compounds can be facilitated by testing potential agents for efficacy, and toxicity using a systematic approach with high throughput screening** e.g., the zebrafish model or mammalian in vitro models (organotypic organ culture, hair cell precursor cultures, such as the UB-OC-1 or HEI-OC1 cell lines). This would allow the screening of a wide range of compounds that could be followed by in vivo testing in mammalian animal models to provide proof of concept for efficacy, mechanisms of action and potential side effects. Ultimately clinical trials will be needed.

The field appears to be moving toward alternative technologies or approaches including **use of stem cells, gene therapy or RNA silencing** using non-viral delivery methods.

Novel developments of drug delivery in the future could provide exciting possibilities to treat hearing loss. The ability to deliver a variety of protective agents by trans-tympanic injection is of great interest as it avoid systemic toxicity and interference with the pharmacokinetics and pharmacodynamics of the aminoglycoside antibiotics or cisplatin.
The field of treatment of hearing loss using medicines is just starting to emerge and offers a wide range of possibilities of intervention. It is hoped that in the following years new compounds will be available to prevent or treat hearing loss.

10. Conclusion

Hearing loss is a major cause of human disability in Europe and in the world. As previously stated 360 million persons have disabling hearing loss in the world in 2012. With the ageing of the world population hearing loss is expected to increase substantially in the future.

Large epidemiological surveys as well as use of standardization methods of evaluation and reporting would certainly help gain awareness of the prevalence and impact of hearing loss in societies.

Rapid advances in bioscience and technology make it realistic to envision a pharmacological treatment for hearing loss of different causes.

There has been exciting research performed towards a possible treatment for hearing loss ranging from the search for new pharmacological compounds, gene therapy, RNA silencing, stem cells, and discovery of new delivery routes of administration.

If at present most of these research have been done in academic settings it is likely that the pharmaceutical industry will also start soon innovative projects towards a pharmacological treatment of hearing loss and that public-private partnerships (PPP) will arise in a relatively short time. As the prevalence of hearing impairment in the world is very high this opens huge potential markets for pharmacological interventions. Consortiums of top-level European research and industrial partners will need to act in this direction and contribute to strengthen the EU’s leadership on research into treatment and pharmacological prevention of hearing loss.

References


Update on 2004 Background Paper, BP 6.21 Hearing Loss


15 Henderson D et al. The role of oxidative stress in noise-induced hearing loss. Ear Hear. 2006; 27:1–19


31 Shield B. Evaluation of the social and economic costs of hearing impairment. 2006. A report for Hear-it. Website: www.hear-it.org


33 Hear-it. Website last visited December 2012. Website: http://www.hear-it.org


37 Hear it Europe, Website last visited December 2012 http://www.hear-it.org/multimedia/Hear_It_Report_October_2006.pdf


Auris Medical: development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders Available at http://www.aurismedical.com/p/therapies/am_111.php?lg=en Last accessed 19 April 2013


Hearing Loss Cure - Stanford University School of Medicine Available at http://hearinglosscure.stanford.edu/ Last accessed on 19 April 2013


Stem Cell Therapy - Hearing Loss Cure - Stanford University School of Medicine Available at http://hearinglosscure.stanford.edu/targeted-neural-stimulation.html Last accessed on 19 April 2013


Annexes

Annex 6.21.1: Countries and territories in analysis regions.

<table>
<thead>
<tr>
<th>Subregion</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>East Asia region</strong></td>
<td>China, Hong Kong SAR (China), Macau SAR (China), Democratic People's Republic of Korea, Taiwan</td>
</tr>
<tr>
<td><strong>Southeast Asia</strong></td>
<td>Cambodia, Indonesia, Lao People's Democratic Republic, Malaysia, Maldives, Myanmar, Philippines, Sri Lanka, Thailand, Timor-Leste, Viet Nam</td>
</tr>
<tr>
<td><strong>Oceania</strong></td>
<td>Cook Islands, Fiji, French Polynesia, Kiribati, Marshall Islands, Micronesia (Federated States of), Nauru, Palau, Papua New Guinea, Samoa, Solomon Islands, Tonga, Vanuatu, Tuvalu, Nieuw-Brisbane</td>
</tr>
<tr>
<td><strong>South Asia region</strong></td>
<td>Afghanistan, Bangladesh, Bhutan, India, Nepal, Pakistan</td>
</tr>
<tr>
<td><strong>Central Asia</strong></td>
<td>Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan</td>
</tr>
<tr>
<td><strong>Central Europe</strong></td>
<td>Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, Macedonia (Former Yugoslav Republic of)</td>
</tr>
<tr>
<td><strong>Eastern Europe</strong></td>
<td>Belarus, Estonia, Latvia, Lithuania, Moldova, Russian Federation, Ukraine</td>
</tr>
<tr>
<td><strong>Middle East and North Africa region</strong></td>
<td>Algeria, Bahrain, Egypt, Iran (Islamic Republic of), Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Occupied Palestinian Territory, Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Tunisia, Turkey, United Arab Emirates, Yemen</td>
</tr>
<tr>
<td><strong>Sub-Saharan Africa region</strong></td>
<td>Angola, Central African Republic, Congo, Democratic Republic of the Congo, Equatorial Guinea, Gabon</td>
</tr>
<tr>
<td><strong>East Africa</strong></td>
<td>Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, Sudan, Uganda, United Republic of Tanzania, Zambia</td>
</tr>
<tr>
<td><strong>Southern Africa</strong></td>
<td>Botswana, Lesotho, Namibia, South Africa, Swaziland, Zimbabwe</td>
</tr>
<tr>
<td><strong>West Africa</strong></td>
<td>Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Côte d'Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, São Tomé and Príncipe, Togo</td>
</tr>
<tr>
<td><strong>Latin America and Caribbean region</strong></td>
<td>Argentina, Chile, Uruguay</td>
</tr>
<tr>
<td><strong>Andean Latin America</strong></td>
<td>Bolivia, Ecuador, Peru</td>
</tr>
<tr>
<td><strong>Central Latin America</strong></td>
<td>Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Venezuela (Bolivarian Republic of)</td>
</tr>
<tr>
<td><strong>Southern Latin America</strong></td>
<td>Argentina, Chile, Uruguay</td>
</tr>
<tr>
<td><strong>Tropical Latin America</strong></td>
<td>Brazil, Paraguay</td>
</tr>
<tr>
<td><strong>Caribbean</strong></td>
<td>Antigua and Barbuda, Bahamas, Barbados, Belize, Bermuda, British Virgin Islands, Cuba, Dominica, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Netherlands Antilles, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago</td>
</tr>
<tr>
<td><strong>High-income region</strong></td>
<td>Brunei Darussalam, Japan, Republic of Korea, Singapore</td>
</tr>
<tr>
<td><strong>Australasia</strong></td>
<td>Australia, New Zealand</td>
</tr>
<tr>
<td><strong>North America, high-income</strong></td>
<td>Canada, United States of America</td>
</tr>
<tr>
<td><strong>Western Europe</strong></td>
<td>Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Greenland, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, San Marino, Monaco, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom</td>
</tr>
</tbody>
</table>
Annex 6.21.2: DALYs caused by hearing loss, by age group, regions and sex*

Data from the Global Burden of Disease 2010, Lancet Dec 2012.

*Created by Faraz Chavoushi, Department of Essential Medicines, World Health Organization, Geneva
Update on 2004 Background Paper, BP 6.21 Hearing Loss

DALY rates caused by hearing loss, by age group and region

Absolute DALYs caused by hearing loss by region and sex

DALY rates caused by hearing loss by sex and region
### Annex 6.21.3: Cochrane study summary on medical interventions

<table>
<thead>
<tr>
<th>Study population</th>
<th>Number of patients</th>
<th>Interventions compared</th>
<th>Results</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus</strong></td>
<td>Any adult with acute onset sensorineural hearing loss and/or tinnitus of any duration.</td>
<td>392 participants 7 trials</td>
<td>Trials using hyperbaric oxygen administered in a compression chamber above 1.2 ATA and for treatment times between 30 and 120 minutes on at least one occasion were eligible. The comparator group was somewhat diverse. We accepted any standard treatment regimen designed to maximise hearing loss recovery or reduction in tinnitus, or where the comparator was designed to improve quality of life for appropriate patients. Subgroup analysis was considered to evaluate the impact of different comparator strategies.</td>
<td>1.53 recovery of hearing as measured by audiometry, Outcome 1 Greater than 50% return of hearing.</td>
</tr>
<tr>
<td><strong>Virals for idiopathic sudden sensorineural hearing loss</strong></td>
<td>Patients of any age with sudden sensorineural hearing loss (ISSHL), defined as follows. A history of a sudden decrease in hearing within three days. A sensorineural hearing loss of at least 30 dB for three subsequent 1-octave steps in frequency, unilateral or bilateral, demonstrable on a standard pure-tone audiogram at the time of entry into the trial. No other neurological signs except for the eighth cranial nerve defect. Commencement of treatment within 14 days of the onset of the hearing loss.</td>
<td>257 participants 4 trials</td>
<td>Antivirals (oral or intravenous). Examples include acyclovir and valacyclovir, given at any dose for any duration. Comparisons were: antiviral versus placebo; antiviral versus no treatment; (antiviral + other treatment) versus (placebo + same other treatment); and (antiviral + other treatment) versus (same other treatment).</td>
<td>There is currently no evidence to support the use of antiviral drugs in the treatment of ISSHL. The four trials included in this review were, however, small and with a low risk of bias. Further randomised controlled trials with larger patient populations, using standardised inclusion criteria, antiviral regimes and outcome measures, are needed in order for adequate meta-analysis to be performed to reach definitive conclusions.</td>
</tr>
<tr>
<td>Study population</td>
<td>Number of patients</td>
<td>Interventions compared</td>
<td>Results</td>
<td>Conclusion</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>--------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Steroids for idiopathic sudden sensorineural hearing loss</td>
<td>164 participants 2 trials</td>
<td>Trials using hyperbaric oxygen administered in a compression chamber above 1.2 ATA and for treatment times between 30 and 120 minutes on at least one occasion were eligible. The comparator group was somewhat diverse. We accepted any standard treatment regimen designed to maximise hearing loss recovery or reduction in tinnitus, or where the comparator was designed to improve quality of life for appropriate patients. Subgroup analysis was considered to evaluate the impact of different comparator strategies.</td>
<td>1.10 Effects of oral steroid versus oral placebo immediate post-treatment, Outcome 1 Hearing recovery: average speech frequencies (500, 1000, 2000 Hz);</td>
<td>No conclusions can be drawn about the effectiveness, or lack thereof, of steroids in the treatment of idiopathic sudden sensorineural hearing loss.</td>
</tr>
<tr>
<td>Corticosteroids for acute bacterial meningitis</td>
<td>4041 participants 24 trials</td>
<td>Participants with community-acquired bacterial meningitis treated with antibacterial agents and randomized to adjuvant corticosteroid therapy of any type.</td>
<td>0.76 Adults, Outcome 2 Any hearing loss.</td>
<td>Corticosteroids significantly reduced hearing loss and neurological sequelae, but did not reduce overall mortality, patients with bacterial meningitis in high-income countries.</td>
</tr>
<tr>
<td>Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children</td>
<td>945 participants 12 trials</td>
<td>Systemic or topical intranasal steroids compared with control (placebo or non-intervention control). We included additional treatments such as antibiotics so long as they were identical in the treatment and in the control groups. We grouped studies according to the comparisons made: (1) oral steroid versus control; (2) oral steroid plus additional treatment versus control plus identical additional treatment; (3) topical intranasal steroid versus control; and (4) topical intranasal steroid plus additional treatment versus control plus identical additional treatment.</td>
<td>Oral steroids versus control, Outcome 1 Hearing loss at six weeks (hearing not improved by at least 10 dB in either ear). 0</td>
<td>No evidence of longer-term benefit and no evidence that they relieve symptoms of hearing loss.</td>
</tr>
</tbody>
</table>
### Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children

<table>
<thead>
<tr>
<th>Study population</th>
<th>Number of patients</th>
<th>Interventions compared</th>
<th>Results</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children aged 1 to 12 years with unilateral or bilateral otitis media with effusion.</td>
<td>376 children 1 trial</td>
<td>Treatment in the form of grommet insertion in the tympanic membrane could be unilateral (randomisation by ears) with no surgery or myringotomy in the other ear as control, or bilateral (randomisation by children) with no surgery or myringotomy alone in the control group.</td>
<td>Hearing levels by child, Outcome 2 By child hearing levels at 12 months follow up: -0.41</td>
<td>No effect was found on other child outcomes but data on these were sparse.</td>
</tr>
</tbody>
</table>

### Medical interventions for the prevention of platinum-induced hearing loss in children with cancer

<table>
<thead>
<tr>
<th>Study population</th>
<th>Number of patients</th>
<th>Interventions compared</th>
<th>Results</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children (aged 0 to 18 years at diagnosis) with any type of childhood malignancy.</td>
<td>total number of patients 149 two RCTs and one CCT</td>
<td>Platinum-based therapy together with a protective medical intervention versus platinum-based therapy with placebo, no additional treatment or another protective medical intervention.</td>
<td>Outcome 2 Ototoxicity according to NCI CTC v2 criteria with intravenous platinum (combined asymptomatic and symptomatic disease): 1.04 Amifostine versus no otoprotective intervention</td>
<td>Since pooling of results was not possible and all studies had serious methodological limitations, no definitive conclusions can be made.</td>
</tr>
</tbody>
</table>